Advertisement
DALLAS, Dec. 27, 2014 /PRNewswire-iReach/ -- New PharmaPoint Country Evaluation report "Colorectal Cancer Japan Drug Forecast and Market Analysis to 2023" provides a data on colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Avastin (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Avastin and Vectibix are not recommended. Complete Report is Available @
http://www.reportsnreports.com/reports/321066-colorectal-cancer-japan-drug-forecast-and-market-analysis-to-2023.html .
Logo - http://photos.prnewswire.com/prnh/20141226/166124LOGO
Japan represents the second-largest market for CRC across the countries covered in this report. Japan is a major CRC market, due to the high incidence of the disease and high drug treatment rates. Increased sales of CRC therapies over the forecast period will be driven by increasing disease incident cases as the population ages, label extension of Stivarga as an adjuvant treatment for resected liver metastases patients, and the launch of expensive new therapies that provide further treatment options for patients in later-line settings, replacing cheaper generic chemotherapy only regimens.
Scope
Reasons to Buy
1 Table of Contents1.1 List of Tables1.2 List of Figures
2 Introduction2.1 Catalyst2.2 Related Reports2.3 Upcoming Related Reports
3 Disease Overview3.1 Etiology and Pathophysiology3.1.1 Etiology3.1.2 Pathophysiology3.2 Clinical Staging3.3 Symptoms
4 Disease Management4.1 Diagnosis and Treatment Overview4.1.1 Screening and Diagnosis4.1.2 Treatment Guidelines and Leading Prescribed Drugs4.1.3 Clinical Practice4.2 Japan4.2.1 Screening and Diagnosis4.2.2 Clinical Practice
5 Competitive Assessment5.1 Overview5.2 Product Profiles Major Brands5.2.1 Avastin (Bevacizumab)5.2.2 Erbitux (Cetuximab)5.2.3 Vectibix (Panitumumab)5.2.4 Stivarga (Regorafenib)5.2.5 Zaltrap (Ziv-Aflibrcept)5.2.6 Lonsurf (TAS-102)5.2.7 TS-1 (Tegafur, Gimeracil, Oteracil)5.2.8 Xeloda (Capecitabine)
6 Unmet Need and Opportunity6.1 Overview6.2 Therapies That Provide Substantial Overall Survival Benefit for Metastatic Patients6.2.1 Unmet Need6.2.2 Gap Analysis6.2.3 Opportunity6.3 Targeted Treatments for KRAS and BRAF Mutaton-Positive Patients6.3.1 Unmet Need6.3.2 Gap Analysis6.3.3 Opportunity6.4 Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease6.4.1 Unmet Need6.4.2 Gap Analysis6.4.3 Opportunity6.5 Tolerable Later-Line Therapies For Chemotherapy-Resistant Patients6.5.1 Unmet Need6.5.2 Gap Analysis6.5.3 Opportunity
7 Pipeline Assessment7.1 Overview7.2 Promising Drugs in Clinical Development7.2.1 Cyramza (Ramucirumab)7.2.2 Nintedanib (BIBF-1120)7.3 Promising Approaches in Early-Stage Development7.3.1 Anti-Angiopoietin-2 Inhibitors7.3.2 Strategies for BRAF Mutation-Positive Disease7.3.3 Strategies for KRAS-Mutation Positive Disease7.3.4 Immune Checkpoint Inhibitors
8 Market Outlook8.1 Japan8.1.1 Forecast8.1.2 Key Events8.1.3 Drivers and Barriers Global Issues8.1.4 Drivers and Barriers
9 Appendix
Inquiry for Discount @ http://www.reportsnreports.com/contacts/Discount.aspx?name=321066 . (This is a premium report priced at US$4995 for a single user License.)
List of Tables
Table 1: TNM and Staging Classification System for CRCTable 2: Symptoms of Colorectal CancerTable 3: Treatment Guidelines for CRCTable 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the US Markets, 2013Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the US Markets, 2013Table 6: Country Profile - JapanTable 7: Leading Treatments for CRC, 2014Table 8: Product Profile AvastinTable 9: Avastin SWOT Analysis, 2014Table 10: Product Profile ErbituxTable 11: Erbitux SWOT Analysis, 2014Table 12: Product Profile VectibixTable 13: Vectibix SWOT Analysis, 2014Table 14: Product Profile StivargaTable 15: Stivarga SWOT Analysis, 2014Table 16: Product Profile ZaltrapTable 17: Zaltrap SWOT Analysis, 2014Table 18: Product Profile LonsurfTable 19: Lonsurf SWOT Analysis, 2014Table 20: Product Profile TS-1Table 21: TS-1 SWOT Analysis, 2014Table 22: Product Profile XelodaTable 23: Unmet Need and Opportunity in CRCTable 24: Product Profile CyramzaTable 25: Cyramza SWOT Analysis, 2014Table 26: Product Profile NintedanibTable 27: Nintedanib SWOT Analysis, 2014Table 28: Anti-Angiopoietin-2 Inhibitors in DevelopmentTable 29: Early-stage Strategies for BRAF Mutation-Positive CRCTable 30: Early-stage Strategies for KRAS Mutation-Positive CRC
Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers. Call +1 888 391 5441 with your research requirements or email the details on [email protected] This e-mail address is being protected from spambots. You need JavaScript enabled to view it and we would be happy to help you find the business intelligence that you need.
Media Contact: Ritesh Tiwari, ReportsnReports, +1888391544, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE ReportsnReports.com
Advertisement
Logo - http://photos.prnewswire.com/prnh/20141226/166124LOGO
Japan represents the second-largest market for CRC across the countries covered in this report. Japan is a major CRC market, due to the high incidence of the disease and high drug treatment rates. Increased sales of CRC therapies over the forecast period will be driven by increasing disease incident cases as the population ages, label extension of Stivarga as an adjuvant treatment for resected liver metastases patients, and the launch of expensive new therapies that provide further treatment options for patients in later-line settings, replacing cheaper generic chemotherapy only regimens.
Scope
- Overview of CRC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Japan from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the Japan CRC market.
Reasons to Buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for CRC
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in Japan.
1 Table of Contents1.1 List of Tables1.2 List of Figures
2 Introduction2.1 Catalyst2.2 Related Reports2.3 Upcoming Related Reports
3 Disease Overview3.1 Etiology and Pathophysiology3.1.1 Etiology3.1.2 Pathophysiology3.2 Clinical Staging3.3 Symptoms
4 Disease Management4.1 Diagnosis and Treatment Overview4.1.1 Screening and Diagnosis4.1.2 Treatment Guidelines and Leading Prescribed Drugs4.1.3 Clinical Practice4.2 Japan4.2.1 Screening and Diagnosis4.2.2 Clinical Practice
5 Competitive Assessment5.1 Overview5.2 Product Profiles Major Brands5.2.1 Avastin (Bevacizumab)5.2.2 Erbitux (Cetuximab)5.2.3 Vectibix (Panitumumab)5.2.4 Stivarga (Regorafenib)5.2.5 Zaltrap (Ziv-Aflibrcept)5.2.6 Lonsurf (TAS-102)5.2.7 TS-1 (Tegafur, Gimeracil, Oteracil)5.2.8 Xeloda (Capecitabine)
6 Unmet Need and Opportunity6.1 Overview6.2 Therapies That Provide Substantial Overall Survival Benefit for Metastatic Patients6.2.1 Unmet Need6.2.2 Gap Analysis6.2.3 Opportunity6.3 Targeted Treatments for KRAS and BRAF Mutaton-Positive Patients6.3.1 Unmet Need6.3.2 Gap Analysis6.3.3 Opportunity6.4 Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease6.4.1 Unmet Need6.4.2 Gap Analysis6.4.3 Opportunity6.5 Tolerable Later-Line Therapies For Chemotherapy-Resistant Patients6.5.1 Unmet Need6.5.2 Gap Analysis6.5.3 Opportunity
7 Pipeline Assessment7.1 Overview7.2 Promising Drugs in Clinical Development7.2.1 Cyramza (Ramucirumab)7.2.2 Nintedanib (BIBF-1120)7.3 Promising Approaches in Early-Stage Development7.3.1 Anti-Angiopoietin-2 Inhibitors7.3.2 Strategies for BRAF Mutation-Positive Disease7.3.3 Strategies for KRAS-Mutation Positive Disease7.3.4 Immune Checkpoint Inhibitors
8 Market Outlook8.1 Japan8.1.1 Forecast8.1.2 Key Events8.1.3 Drivers and Barriers Global Issues8.1.4 Drivers and Barriers
9 Appendix
Inquiry for Discount @ http://www.reportsnreports.com/contacts/Discount.aspx?name=321066 . (This is a premium report priced at US$4995 for a single user License.)
List of Tables
Table 1: TNM and Staging Classification System for CRCTable 2: Symptoms of Colorectal CancerTable 3: Treatment Guidelines for CRCTable 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the US Markets, 2013Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the US Markets, 2013Table 6: Country Profile - JapanTable 7: Leading Treatments for CRC, 2014Table 8: Product Profile AvastinTable 9: Avastin SWOT Analysis, 2014Table 10: Product Profile ErbituxTable 11: Erbitux SWOT Analysis, 2014Table 12: Product Profile VectibixTable 13: Vectibix SWOT Analysis, 2014Table 14: Product Profile StivargaTable 15: Stivarga SWOT Analysis, 2014Table 16: Product Profile ZaltrapTable 17: Zaltrap SWOT Analysis, 2014Table 18: Product Profile LonsurfTable 19: Lonsurf SWOT Analysis, 2014Table 20: Product Profile TS-1Table 21: TS-1 SWOT Analysis, 2014Table 22: Product Profile XelodaTable 23: Unmet Need and Opportunity in CRCTable 24: Product Profile CyramzaTable 25: Cyramza SWOT Analysis, 2014Table 26: Product Profile NintedanibTable 27: Nintedanib SWOT Analysis, 2014Table 28: Anti-Angiopoietin-2 Inhibitors in DevelopmentTable 29: Early-stage Strategies for BRAF Mutation-Positive CRCTable 30: Early-stage Strategies for KRAS Mutation-Positive CRC
Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers. Call +1 888 391 5441 with your research requirements or email the details on [email protected] This e-mail address is being protected from spambots. You need JavaScript enabled to view it and we would be happy to help you find the business intelligence that you need.
Media Contact: Ritesh Tiwari, ReportsnReports, +1888391544, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE ReportsnReports.com
